Skip to Main Content

Author Details

Anna M Piskorz
CRUK Cambridge Institute, University of Cambridge
2007
41
21
PMIDPaper TitleJournal TitlePublished Year
36368129Profiling the immune landscape in mucinous ovarian carcinoma.Gynecol Oncol2023
37752102Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.Nat Commun2023
37845213Molecular landscape and functional characterization of centrosome amplification in ovarian cancer.Nat Commun2023
37875466Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer.Nat Commun2023
37444472Identification of Tissue-Resident Natural Killer and T Lymphocytes with Anti-Tumor Properties in Ascites of Ovarian Cancer Patients.Cancers (Basel)2023
37474499The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.Nat Commun2023
34697060DNA Methylation Profiles of Ovarian Clear Cell Carcinoma.Cancer Epidemiol Biomarkers Prev2022
35398881The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.Clin Cancer Res2022
35816189Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes.Clin Cancer Res2022
36456881The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer.Nat Genet2022
36289203Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer.Nat Commun2022
33720084Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies.Int J Gynecol Pathol2022
32546565Population-based targeted sequencing of 54 candidate genes identifies <i>PALB2</i> as a susceptibility gene for high-grade serous ovarian cancer.J Med Genet2021
33570999FrenchFISH: Poisson Models for Quantifying DNA Copy Number From Fluorescence In Situ Hybridization of Tissue Sections.JCO Clin Cancer Inform2021
32360491Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma.Hum Pathol2020
31829441p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.J Pathol2020
32249277Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma.Br J Cancer2020
32554541Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).Clin Cancer Res2020
32473302Prognostic gene expression signature for high-grade serous ovarian cancer.Ann Oncol2020
30404863Enhanced detection of circulating tumor DNA by fragment size analysis.Sci Transl Med2018
30165204Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients.J Mol Diagn2018
30104763Copy number signatures and mutational processes in ovarian carcinoma.Nat Genet2018
30248946Selected Socio-Demographic and Occupational Factors of Burnout Syndrome in Nurses Employed in Medical Facilities in Maſopolska-Preliminary Results.Int J Environ Res Public Health2018
28881617Germline whole exome sequencing and large-scale replication identifies <i>FANCM</i> as a likely high grade serous ovarian cancer susceptibility gene.Oncotarget2017
28359078Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.Br J Cancer2017
28346442Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Nat Genet2017
26681675Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samples.Ann Oncol2016
26598982Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience.Int J Gynecol Pathol2016
27840695Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma.J Pathol Clin Res2016
27997533Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study.PLoS Med2016
25710373Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis.PLoS Med2015
26528104Comparison of SCORE-predicted risk of death due to cardiovascular events in women before and after menopause.Prz Menopauzalny2015
24810481Conditions associated with circulating tumor-associated folate receptor 1 protein in healthy men and women.PLoS One2014
25230021Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes.PLoS One2014
23563269Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.Nature2013
21344236Cancer predisposing BARD1 mutations in breast-ovarian cancer families.Breast Cancer Res Treat2012
22649089Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.Sci Transl Med2012
21527588Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience.Ann Oncol2012
21362052A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.Eur J Haematol2011
21689725Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.Exp Hematol2011
17711100[Influence of nutrition on selected metabolic cardiovascular risk factors among female residents of Krakow].Rocz Panstw Zakl Hig2007
  • 1 - 41 of 41

Recommended Authors

Pier Selenica
Memorial Sloan Kettering Cancer Center
Career Start Year 2017
Number of shared co-authors 12
Arnaud Da Cruz Paula
Memorial Sloan Kettering Cancer Center
Career Start Year 2014
Number of shared co-authors 5
Nicholas C Spies
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2013
Number of shared co-authors 1
Yuexin Liu
The University of Texas MD Anderson Cancer Center
Career Start Year 2011
Number of shared co-authors 6
Ghassan Allo
Henry Ford Hospital
Career Start Year 2011
Number of shared co-authors 9
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 1
Gabriele Zoppoli
University of Genoa and Ospedale Policlinico San Martino
Career Start Year 2008
Number of shared co-authors 2
Salvatore Piscuoglio
University of Basel
Career Start Year 2008
Number of shared co-authors 5
Francine B de Abreu
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2007
Number of shared co-authors 2
Nicola Waddell
QIMR Berghofer Medical Research Institute
Career Start Year 2006
Number of shared co-authors 48
Albrecht Stenzinger
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2005
Number of shared co-authors 6
Markus Riester
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 2
Caterina Marchi??
University of Turin, Candiolo Cancer Institute, FPO-IRCCS
Career Start Year 2005
Number of shared co-authors 3
Leah M Prentice
British Columbia Women's Hospital and Health Centre
Career Start Year 2004
Number of shared co-authors 40
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2004
Number of shared co-authors 3
Andrew H Beck
Beth Israel Deaconess Medical Center, Harvard Medical School
Career Start Year 2004
Number of shared co-authors 28
Peter Horak
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Career Start Year 2003
Number of shared co-authors 2
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 7
Olivier Harismendy
University of California
Career Start Year 2003
Number of shared co-authors 1
Frederick Klauschen
Institute of Pathology, Ludwig-Maximilians-Universitat Munchen
Career Start Year 2002
Number of shared co-authors 5
Olaf Neumann
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2002
Number of shared co-authors 2
Volker Endris
Institute of Pathology, University Hospital Heidelberg
Career Start Year 2001
Number of shared co-authors 6
Blaise A Clarke
University of Toronto.
Career Start Year 2001
Number of shared co-authors 51
Steve E Kalloger
University of British Columbia
Career Start Year 2000
Number of shared co-authors 31
Luciano G Martelotto
Monash University
Career Start Year 2000
Number of shared co-authors 3
Andrea Sboner
Institute for Computational Biomedicine
Career Start Year 2000
Number of shared co-authors 2
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Career Start Year 1999
Number of shared co-authors 9
Jan Budczies
Institute of Pathology, University Hospital Heidelberg
Career Start Year 1996
Number of shared co-authors 5
John W M Martens
Erasmus Medical Center (MC) Cancer Institute
Career Start Year 1989
Number of shared co-authors 94
Jeffrey S Ross
Foundation Medicine
Career Start Year 1974
Number of shared co-authors 3

Collaborators

James D Brenton
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 32
Mercedes Jimenez-Linan
University of Cambridge
Co-authored papers 16
Teodora Goranova
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 13
Iain A McNeish
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 12
Darren Ennis
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 10
Geoff Macintyre
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 9
Martin K??bel
University of Calgary
Co-authored papers 9
Ellen L Goode
Mayo Clinic College of Medicine
Co-authored papers 8
Paul D P Pharoah
Center for Cancer Genetic Epidemiology, University of Cambridge
Co-authored papers 8
Catherine J Kennedy
The Westmead Institute for Medical Research, University of Sydney
Co-authored papers 8
David G Huntsman
University of British Columbia
Co-authored papers 8
Anna DeFazio
Westmead Hospital
Co-authored papers 8
Cyril B Gilks
University of British Columbia
Co-authored papers 7
Naveena Singh
Barts Health NHS Trust
Co-authored papers 7
Stacey J Winham
Mayo Clinic
Co-authored papers 7
Simon A Gayther
Cedars-Sinai Medical Center
Co-authored papers 7
Susan J Ramus
School of Clinical Medicine, University of NSW Sydney, Lowy Cancer Research Centre
Co-authored papers 7
Jenny Lester
David Geffen School of Medicine, University of California at Los Angeles
Co-authored papers 7
Florian Markowetz
CRUK Cambridge Institute, University of Cambridge
Co-authored papers 7
Beth Y Karlan
David Geffen School of Medicine, University of California los angeles
Co-authored papers 6
Liz-Anne Lewsley
CRUK Clinical Trials Unit, University of Glasgow
Co-authored papers 6
Celeste Leigh Pearce
University of Michigan School of Public Health ann arbor
Co-authored papers 6
David D L Bowtell
Peter MacCallum Cancer Centre
Co-authored papers 6
Usha Menon
College of Nursing, University of South Florida
Co-authored papers 6
Matthew D Eldridge
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 6
Yoke-Eng Chiew
Westmead Hospital
Co-authored papers 5
Holly R Harris
Fred Hutchinson Cancer Center, University of Washington
Co-authored papers 5
Honglin Song
University of Cambridge
Co-authored papers 5
Jennifer A Doherty
Huntsman Cancer Institute, University of Utah
Co-authored papers 5
Rosalind Glasspool
University of Glasgow
Co-authored papers 5
Release 1.2